The Polish Interventional Cardiology TAVI Survey (PICTS): 10 years of transcatheter aortic valve implantation in Poland. The landscape after the first stage of Valve for Life initiative

Dąbrowski, M; Parma, Radosław; Huczek, Zenon; Jagielak, Dariusz; Grygier, Marek; Trębacz, Jarosław; Dębiński, Marcin; Kübler, Piotr; Kochman, Janusz; Witkowski, Adam; Wojakowski, Wojciech

doi:10.20452/pamw.15887

Cited by 8 publications

(11 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While first TAVI cohorts included only patients disqualified from surgical aortic valve replacement (SAVR), currently, a variety of subjects with low to high perioperative risk and low to severe comorbidity undergo the procedure. [1][2][3] The treated population is diverse; therefore, several issues should be evaluated, including the qualification process and the follow-up management, to obtain the best therapeutic results.…”

Section: Introductionmentioning

confidence: 99%

Neutrophil-to-lymphocyte ratio as a predictor of inflammatory response in patients with acute kidney injury after transcatheter aortic valve implantation

Olasińska-Wiśniewska¹,

Urbanowicz²,

Grodecki³

et al. 2022

Adv Clin Exp Med

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Neutrophil-to-lymphocyte ratio as a predictor of inflammatory response in patients with acute kidney injury after transcatheter aortic valve implantation

Olasińska-Wiśniewska¹,

Urbanowicz²,

Grodecki³

et al. 2022

Adv Clin Exp Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…This tendency has been seen for many years. 11 In 2020, the numbers of SAVR and TAVI procedures were almost equal. The shift to less invasive procedures was associated with a decline in the length of hospitalization 12 and may be linked to reduced exposure to medical personnel.…”

Section: Discussionmentioning

confidence: 99%

Changes in treatment of aortic valve diseases for acute and elective indications during the COVID-19 pandemic: A retrospective single-center analysis from 2019 to 2020

Cierpiszewska¹,

Ciechanowicz²,

Górecki³

et al. 2022

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. Coronavirus disease 2019 (COVID-19) pandemic had an impact on the quality of healthcare services and led to many changes in the treatment of cardiac pathologies. Objectives.To assess the differences in the clinical manifestations, management and outcomes of patients with aortic valve diseases (AVDs) treated invasively before and during the pandemic. Materials and methods.This retrospective single-center study involved patients with AVDs treated by means of balloon aortic valvuloplasty (BAV), transcatheter aortic valve implantation (TAVI) or surgical aortic valve replacement (SAVR) in 2019 and 2020. They were divided into groups with respect to the year of intervention (2019 compared to 2020) and the priority of admission (urgent compared to elective). Preoperative characteristics, early outcomes and probability of annual survival were compared between the groups.Results. The number of patients admitted urgently increased from 37 in 2019 to 54 in 2020, with a higher prevalence of men in 2020 (83.3% compared to 56.8%, respectively). Elective cases, on the other hand, declined from 279 in 2019 to 256 in 2020. Among the latter, more subjects had manifestations of heart failure (p < 0.001), coronary artery disease (CAD; p = 0.002), hypertension (p = 0.006), as well as had a history of a stroke (p = 0.002). In the meantime, more TAVI and fewer SAVR procedures were performed in 2020 (86 compared to 127 and 192 compared to 125, respectively; p < 0.001). In 2020, TAVI individuals had risk of death (according to the EuroSCORE scale) than in 2019 (p < 0.001). The probability of annual survival was comparable (p = 0.769) among AVD patients treated before and during the coronavirus pandemic (91.3% compared to 88.3%, respectively). Conclusions.Although during the COVID-19 pandemic more nonelective and higher-risk AVD individuals received interventional treatment, the outcomes were comparable to the pre-pandemic era (2019). Our findings support highly valuable, less invasive therapeutic methods for treating aortic pathologies during the pandemic.

show abstract

“…The numerical increase in ViV-TAVI reflected an increase in the total number of TAVI each year with the biggest gain observed since 2018 (n=59, 45% of all) (Figure 1). Throughout the study period, ViV-TAVI constituted on average 1.9% of all TAVI in Poland [11]. Mean number of ViV-TAVI per center was 9.3, but with only 3 centers having performed more than 10 procedures.…”

Section: Frequency Of Viv-tavi and Baseline Characteristicsmentioning

confidence: 99%

“…SAV stenosis at baseline compared to regurgitation or mixed disease was associated with higher average PG (median [IQR] 16[13.5-22.5] vs. 14.5[10][11][12][13][14][15][16][17][18][19] mmHg, P=0.004). ViV-TAVI performed in small SAV's (≤21 mm) was associated with smaller post-procedural effective orifice area (EOA) as compared with bigger SAV's (1.4 [1.2-1.6] vs. 1.58 [1.45-1.7], P=0.005) (Supplementary material, FigureS2, panel 2).…”

mentioning

confidence: 99%

Transcatheter aortic valve-in-valve implantation for failed surgical bioprostheses: results from Polish Transcatheter Aortic Valve-in-Valve Implantation (ViV-TAVI) Registry

Huczek¹,

Jędrzejczyk²,

Jagielak³

et al. 2021

Polish Archives of Internal Medicine

Self Cite

View full text Add to dashboard Cite

Lecture honoraria -Edwards Lifesciences) Name of the trial registry: Polish Transcatheter Aortic Valve-in-Valve Implantation (ViV-TAVI) Registry ClinicalTrials.gov Identifier: NCT03361046 URL of the registry: https://clinicaltrials.gov/ct2/show/NCT03361046 WHAT'S NEW?Patients with failed surgical aortic bioprostheses requiring transcatheter valve-in-valve procedures constitute a very specific TAVI population that is expected to grow in the future.The present study reports the results from Polish Transcatheter Aortic Valve-in-Valve Implantation (ViV-TAVI) Registry in order to better understand frequency, characteristics, safety, and efficacy of this novel procedure in Poland.

show abstract

The Polish Interventional Cardiology TAVI Survey (PICTS): 10 years of transcatheter aortic valve implantation in Poland. The landscape after the first stage of Valve for Life initiative

Cited by 8 publications

References 23 publications

Neutrophil-to-lymphocyte ratio as a predictor of inflammatory response in patients with acute kidney injury after transcatheter aortic valve implantation

Neutrophil-to-lymphocyte ratio as a predictor of inflammatory response in patients with acute kidney injury after transcatheter aortic valve implantation

Changes in treatment of aortic valve diseases for acute and elective indications during the COVID-19 pandemic: A retrospective single-center analysis from 2019 to 2020

Transcatheter aortic valve-in-valve implantation for failed surgical bioprostheses: results from Polish Transcatheter Aortic Valve-in-Valve Implantation (ViV-TAVI) Registry

Contact Info

Product

Resources

About